Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia

Journal of Neuroimmunology

Volumn 251, Issue 1-2, 2012, Pages 73-79

  Martins, Luiza Conceição Amorim ^a   Rocha, Natália Pessoa ^a   Torres, Karen Cecília Lima ^a   dos Santos, Rodrigo Ribeiro ^a   França, Giselle Sabrina ^a   de Moraes, Edgar Nunes ^a   Mukhamedyarov, Marat Alexandrovich ^b   Zefirov, Andrey Lvovich ^b   Rizvanov, Albert Anatolyevich ^b,c,d,e   Kiyasov, Andrey Pavlovich ^b,e   Vieira, Luciene Bruno ^a   Guimarães, Melissa Monteiro ^a,f   Yalvaç, Mehmet Emir ^d   Teixeira, Antônio Lúcio ^a   Bicalho, Maria Aparecida Camargo ^a   Janka, Zoltán ^g   Romano Silva, Marco Aurélio ^a   Palotás, András ^h   Reis, Helton José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^d YEDITEPE UNIVERSITY   (Turkey)

^e Republic Clinical Hospital   (Russian Federation)

^f UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

^g UNIVERSITY OF SZEGED   (Hungary)

^h Asklepios Med (Private Medical Practice and Research Center)   (Hungary)

Author keywords

amyloid peptide; Aging; Alzheimer's disease; Dopamine receptor; Leukocyte; Natural killer (NK) cell; Peripheral blood mono nuclear cell (PBMC); Serotonin receptor

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONINERGIC SYSTEM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPRESSION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN;

EID: 84865625787     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.06.003     Document Type: Article

References (63)

1. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7(2):208-244.
2. Andrews J.A., Neises K.D. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. J. Neurochem. 2012, 120(1):26-36.
3. Araga S., Kagimoto H., Funamoto K., Adachi A., Inoue K., Takahashi K. Natural killer cell activity in patients with dementia of the Alzheimer type. Arch. Neurol. 1990, 47(4):380-381.
4. Araga S., Kagimoto H., Funamoto K., Takahashi K. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol. Scand. 1991, 84(3):259-263.
5. 2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev. 2000, 120(1-3):65-75.
6. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
7. Bertolucci P.H., Brucki S.M., Campacci S.R., Juliano Y. The mini-mental state examination in a general population: impact of educational status. Arq. Neuropsiquiatr. 1994, 52(1):1-7.
8. + T cells. J. Neuroimmunol. 2006, 173(1-2):180-187.
9. Calciano M.A., Zhou W., Snyder P.J., Einstein R. Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells. Alzheimers Dement. 2010, 6(5):386-393.
10. Chen K.H., Reese E.A., Kim H.W., Rapoport S.I., Rao J.S. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J. Alzheimers Dis. 2011, 26(4):755-766.
11. Chen M.L., Tsai T.C., Lin Y.Y., Tsai Y.M., Wang L.K., Lee M.C., Tsai F.M. Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. Immunol. Lett. 2011, 140(1-2):81-91.
12. Connolly G.P. Fibroblast models of neurological disorders: fluorescence measurement studies. Trends Pharmacol. Sci. 1998, 19(5):171-177.
13. Corder E.H., Robertson K., Lannfelt L., Bogdanovic N., Eggertsen G., Wilkins J., Hall C. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat. Med. 1998, 4(10):1182-1184.
14. Cross A.J., Slater P., Perry E.K., Perry R.H. An autoradiographic analysis of serotonin receptors in human temporal cortex: changes in Alzheimer-type dementia. Neurochem. Int. 1988, 13(1):89-96.
15. Cummings J.L., Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am. J. Geriatr. Psychiatry 1998, 6(2 Suppl. 1):S64-S78.
16. Dolman C.L. Diagnosis of neurometabolic disorders by examination of skin biopsies and lymphocytes. Semin. Diagn. Pathol. 1984, 1(2):82-97.
17. Dubois B., Feldman H.H., Jacova C., deKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
18. Dumery L., Bourdel F., Soussan Y., Fialkowsky A., Viale S., Nicolas P., Reboud-Ravaux M. β-amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. Pathol. Biol. (Paris) 2001, 49:72-85.
19. Engelborghs S., deBrabander M., deCrée J., d'Hooge R., Geerts H., Verhaegen H., deDeyn P.P. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem. Int. 1999, 34(6):523-530.
20. Esiri M.M. Viruses and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1982, 45(8):759-760.
21. Etcheberrigaray R., Hirashima N., Nee L., Prince J., Govoni S., Racchi M., Tanzi R.E., Alkon D.L. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol. Dis. 1998, 5(1):37-45.
22. Fehér A., Juhász A., Rimanóczy A., Kálmán J., Janka Z. Association study of interferon-γ, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease. Am. J. Geriatr. Psychiatry 2010, 18(11):983-987.
23. Gambi F., Reale M., Iarlori C., Salone A., Toma L., Paladini C., De Luca G., Feliciani C., Salvatore M., Salerno R.M., Theoharides T.C., Conti P., Exton M., Gambi D. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol. 2004, 24(3):314-321.
24. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., Ramirez M.J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43(3):442-449.
25. Garssadi S.I., Mándi Y., Régely K., Taródi B., Béládi I. The inhibitory effect of interferon-α on the serotonin-induced impairment of human NK cell activity in whole blood. Brain Behav. Immun. 1993, 7(2):164-175.
26. Giorelli M., Livrea P., Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-β. J. Interferon Cytokine Res. 2005, 25(7):395-406.
27. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
28. Hersch E.C., Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin. Interv. Aging 2007, 2(4):611-621.
29. Idoate-Gastearena M.A., Vega-Vázquez F. Diagnosis of neurometabolic and neurodegenerative diseases by cutaneous biopsy. Rev. Neurol. 1997, 25(Suppl. 3):S269-S280.
30. 2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neurosci. Lett. 1993, 154(1-2):171-174.
31. 2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 1998, 19(6):472-480.
32. 2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci. 2003, 18(1):149-154.
33. 5R) in Alzheimer's disease brain. Brain Res. 2007, 1131(1):187-196.
34. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev. 2006, 127(2):158-165.
35. Llano, D.A., Li, J., Waring, J.F., Ellis, T., Devanarayan, V., Witte, D.G., Lenz, R.A., in press. Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. Alzheimer Dis. Assoc. Disord.
36. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine-2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(3):702-721.
37. Martin C., Solís L., Concha M.I., Otth C. Herpes simplex virus type 1 as risk factor associated to Alzheimer disease. Rev. Med. Chil. 2011, 139(6):779-786.
38. Martorana A., Esposito Z., Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?. CNS Neurosci. Ther. 2010, 16(4):235-245.
39. Masera R.G., Prolo P., Sartori M.L., Staurenghi A., Griot G., Ravizza L., Dovio A., Chiappelli F., Angeli A. Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease. Psychoneuroendocrinology 2002, 27(4):447-461.
40. Miklóssy J. Emerging roles of pathogens in Alzheimer disease. Expert Rev. Mol. Med. 2011, 13:e30.
41. 3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996, 46(3):791-795.
42. Oláh T., Ocsovszki I., Mándi Y., Pusztai R., Bakay M., Bálint E. Opposite effects of serotonin and interferon-α on the membrane potential and function of human natural killer cells. In Vitro Cell. Dev. Biol. Anim. 2005, 41(5-6):165-170.
43. Parnetti L., Amici S., Lanari A., Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech. Ageing Dev. 2001, 122(16):2063-2069.
44. Proitsi P., Lupton M.K., Reeves S.J., Hamilton G., Archer N., Martin B.M., Iyegbe C., Hollingworth P., Lawlor B., Gill M., Brayne C., Rubinsztein D.C., Owen M.J., Williams J., Lovestone S., Powell J.F. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol. Aging 2012, 33(4):791-803.
45. Pytliak M., Vargová V., Mechírová V., Felšöci M. Serotonin receptors - from molecular biology to clinical applications. Physiol. Res. 2011, 60(1):15-25.
46. Reale M., Iarlori C., Gambi F., Feliciani C., Salone A., Toma L., DeLuca G., Salvatore M., Conti P., Gambi D. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J. Neuroimmunol. 2004, 148(1-2):162-171.
47. Reale M., Iarlori C., Feliciani C., Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimers Dis. 2008, 14(2):147-159.
48. 3) receptor availability and delusions in Alzheimer disease. Neurology 2009, 72(6):528-534.
49. Rocca P., De Leo C., Eva C., Marchiaro L., Milani A.M., Musso R., Ravizza L., Zanalda E., Bogetto F. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26(6):1155-1160.
50. 4 dopamine receptors in leukocytes is related to schizophrenic symptoms. Schizophr. Res. 2005, 80(2-3):363-365.
51. Selkoe D.J. Alzheimer's disease: genes, proteins and therapy. Physiol. Rev. 2001, 81:741-766.
52. Shearman E., Rossi S., Szász B., Jurányi Z., Fallon S., Pomara N., Sershen H., Lajtha A. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res. Bull. 2006, 69(2):204-213.
53. Solerte S.B., Cravello L., Ferrari E., Fioravanti M. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 917:331-340.
54. 2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia. Int. Psychogeriatr. 2000, 12(4):537-545.
55. Sy M., Kitazawa M., Medeiros R., Whitman L., Cheng D., Lane T.E., Laferla F.M. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am. J. Pathol. 2011, 178(6):2811-2822.
56. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science (Wash DC) 1999, 286:2352-2355.
57. Teixeira A.L., Reis H.J., Coelho F.M., Carneiro D.S., Teixeira M.M., Vieira L.B., Mukhamedyarov M.A., Zefirov A.L., Janka Z., Palotás A. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's β-amyloid peptide. Biol. Psychiatry 2008, 64(10):891-895.
58. Torres K.C., Souza B.R., Miranda D.M., Nicolato R., Neves F.S., Barros A.G., Dutra W.O., Gollob K.J., Correa H., Romano-Silva M.A. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):214-219.
59. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989, 47:187-376.
60. 3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 2004, 50(4):305-310.
61. Wilkins C.H., Mathews J., Sheline Y.I. Late life depression with cognitive impairment: evaluation and treatment. Clin. Interv. Aging 2009, 4:51-57.
62. Xia Z., DePierre J.W., Nässberger L. Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology 1996, 34(1):27-37.
63. Yamamoto T., Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann. Neurol. 1985, 17(6):573-577.